David Dean Halbert serves as Chief Executive Officer of Caris Life Sciences Inc., a leader in precision medicine and molecular profiling for oncology. With more than 30 years of experience in the life sciences industry, Halbert has built a distinguished career marked by transformative leadership in clinical research, biopharmaceutical services, and healthcare innovation. His expertise spans contract research organizations (CROs), commercialization strategies, and data-driven solutions, positioning him as a pivotal figure in advancing patient outcomes through technology and science. Before joining Caris in 2018, Halbert was CEO of Syneos Health, where he spearheaded the 2017 merger of INC Research and inVentiv Health, creating a global biopharmaceutical solutions powerhouse with over 23,000 employees and annual revenues exceeding $2 billion. Under his guidance, the company expanded its integrated offerings in clinical development and commercialization, earning recognition for operational excellence and growth. Earlier roles included President of inVentiv Health, CEO of its Clinical Development Solutions division, and senior executive positions at PRA International and Quintiles Transnational (now IQVIA), where he honed skills in global operations, strategic partnerships, and regulatory navigation. At Caris Life Sciences, Halbert has accelerated the company's mission to deliver AI-powered molecular intelligence, including the Caris Molecular Intelligence® platform, which profiles tumors at unprecedented depth to guide personalized cancer therapies. His leadership has driven significant advancements in biomarker discovery, clinical trial matching, and real-world evidence generation, expanding Caris's impact on over 400,000 patients worldwide. Halbert's vision continues to propel Caris toward redefining precision oncology through cutting-edge technology and collaborative research.